BBNXHealthcare · Medical DevicesThe 12 Wall Street analysts covering Beta Bionics, Inc. hold a median 12-month price target of $20 — +5.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 22 Aug 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Beta Bionics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (66): Analysts have, on balance, been raising their forecasts.
Quality (29): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BBNX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +5.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 Aug 2026 | William Blair | Initiates | Market Perform | — |
| 28 July 2026 | UBS | Assumes | Buy | $22 |
| 15 July 2026 | Goldman Sachs | Maintains | Buy | — |
| 15 July 2026 | Goldman Sachs | Maintains | Buy | $17 → $19 |
| 13 July 2026 | Truist Securities | Maintains | Buy | $18 → $22 |
| 13 July 2026 | Truist Securities | Maintains | Buy | — |
| 27 May 2026 | Goldman Sachs | Maintains | Buy | — |
| 18 May 2026 | B of A Securities | Maintains | Neutral | — |
| 22 Apr 2026 | Leerink Partners | Maintains | Outperform | — |
| 22 Apr 2026 | Stifel | Maintains | Buy | — |
| 15 Apr 2026 | Truist Securities | Maintains | Buy | — |
| 9 Apr 2026 | Goldman Sachs | Maintains | Buy | — |
| 18 Feb 2026 | Baird | Maintains | Neutral | — |
| 18 Feb 2026 | Stifel | Maintains | Buy | — |
| 4 Feb 2026 | Stifel | Maintains | Buy | — |
| 2 Feb 2026 | Truist Securities | Maintains | Buy | — |
| 27 Jan 2026 | TD Cowen | Initiates | Hold | — |
| 9 Jan 2026 | Lake Street | Maintains | Buy | — |
| 5 Jan 2026 | B of A Securities | Maintains | Buy | — |
| 18 Dec 2025 | Truist Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BBNX appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 93% of US stocks
Cheaper than 18% of US stocks
Cheaper than 31% of US stocks
Cheaper than 83% of US stocks
Higher than 82% of US stocks
Higher than 70% of US stocks
Higher than 73% of US stocks
Higher than 14% of US stocks
Higher than 9% of US stocks
Higher than 28% of US stocks
Higher than 22% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Beta Bionics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
William Blair initiated coverage on Tandem Diabetes Care and Beta Bionics, noting that both companies are advancing initiatives to compete in faster-growing segments of the insulin pump market.
Why it matters — The coverage highlights Beta Bionics' efforts to position itself in expanding areas of the insulin pump market, drawing analyst attention to its growth prospects.
Johnson Fistel, PLLP announced it is investigating potential securities law violations on behalf of Beta Bionics, Inc. (NASDAQ: BBNX) shareholders. The investigation focuses on whether the company or certain executive officers made false or misleading statements or failed to disclose material information regarding growth trends, new patient starts, business outlook, and related operating metrics.
Why it matters — BBNX watchers would care because the investigation raises the possibility of undisclosed issues with the company's reported growth and operating metrics.
Johnson Fistel, PLLP is investigating potential securities law violations by Beta Bionics, alleging that the company or its executives may have made false or misleading statements or failed to disclose material information regarding growth trends, new patient starts, business outlook, and related operating metrics.
Why it matters — Shareholders should be aware of the investigation as it raises questions about the accuracy of Beta Bionics' public disclosures and could lead to legal liabilities or penalties.
Beta Bionics, Inc. held its Q2 2026 earnings call and the transcript was published by Seeking Alpha.
Why it matters — Earnings call transcripts provide direct insight into management's discussion of quarterly performance and outlook.
Beta Bionics reported a Q2 loss of $0.53 per share, narrower than the Zacks Consensus Estimate of a $0.62 loss but wider than the $0.39 per share loss from the same quarter last year.
Why it matters — The company's quarterly loss came in smaller than analysts had anticipated, indicating performance that exceeded expectations on the bottom line.
The 12 Wall Street analysts covering Beta Bionics, Inc. have a median 12-month price target of $20, with estimates ranging from $14 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Beta Bionics, Inc., 8 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Beta Bionics, Inc. 36 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Beta Bionics, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (66 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +5.0% from the last close, and Ticker Nerd's factor model ranks Beta Bionics, Inc. 36 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Beta Bionics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BBNX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $30 over the next 12 months.
Beta Bionics, Inc. returned +12.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Beta Bionics Inc. is a commercial-stage medical device company focused on designing, developing, and commercializing advanced solutions to improve the health and quality of life for people requiring insulin due to diabetes.
The most recent item we track (Benzinga, 21 Aug 2026): "Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics". William Blair initiated coverage on Tandem Diabetes Care and Beta Bionics, noting that both companies are advancing initiatives to compete in faster-growing segments of the insulin pump market.
Beta Bionics Inc. is a commercial-stage medical device company focused on designing, developing, and commercializing advanced solutions to improve the health and quality of life for people requiring insulin due to diabetes. Its flagship product, the iLet Bionic Pancreas, is an FDA-cleared automated insulin delivery system for treating type 1 diabetes in adults and children aged six and older. This innovative device autonomously calculates and delivers 100% of insulin doses using data from compatible continuous glucose monitors like Dexcom or FreeStyle Libre 3 Plus, eliminating the need for carb counting or manual corrections. The company offers the recently introduced Color iLet with an enhanced color screen, brighter display, and louder alerts. Beta Bionics Inc. is also advancing a Patch Pump that adheres directly to the skin without tubing, a Bihormonal iLet combining insulin and glucagon delivery, and an iLet for insulin-dependent type 2 diabetes. It maintains collaborations with Xeris Pharmaceuticals for pump-compatible glucagon and Abbott Diabetes Care for automated insulin delivery systems. Founded in 2015 and headquartered in Irvine, California, Beta Bionics Inc. serves the diabetes community through durable medical equipment and pharmacy benefit plan channels, including a Pharmacy Advantage Program offering the first 30 days free.
CEO Mr. Sean T. Saint PE · 420 employees · United States · https://www.betabionics.com